Podcasts about MEDLINE

Every spring, the MBA program at the William & Mary School of Business presents the Principled Achievement Award to a leader who best embraces and demonstrates the tenets of principled achievement. Previous winners include the head coach of the Buffalo Bills, Sean McDermott; and AnnaMaria DeSalva, global chairman of Burson, the global communication company. The Principled Achievement Award winner is the leader who values people, diversity of thought, empathy, humility, integrity and success. This year's winner is Michael Medline, CEO of Empire Company and Sobeys Inc – Canada's second largest retailer, whose key businesses include Sobeys, Safeway, IGA, and others. Medline joins us to discuss principled achievement, leadership, and how doing things the right way is the only way.  Learn how the Raymond A. Mason School of Business at William and Mary can help you and your organization develop your top talent through customized executive education and professional development programs. Visit us at www.wmleadership.com. Thank you for listening.

E&I Host:  Allison Lambert, E&I Category Marketing ManagerGuest: Teresa Pugliese, VP of Sales, Geri-CareDiscover how Geri-Care Pharmaceuticals equips institutions with essential over-the-counter (OTC) products to address student health needs year-round. In this episode of Cooperatively Speaking, Teresa Pugliese, Vice President of Sales at Geri-Care, discusses their extensive product line—including pain relievers, allergy medications, and digestive aids—tailored for campus health centers and stores. She emphasizes proactive approaches to health management, the importance of accessible care, and Geri-Care's plans to enhance student wellness initiatives. Geri-Care products and services are available through E&I's Medline contract.  Relevant Links:E&I Medline ContractCooperatively Speaking is hosted by E&I Cooperative Services, the only member-owned, non-profit procurement cooperative exclusively focused on serving the needs of education. Visit our website at www.eandi.org/podcast.Contact UsHave questions, comments, or ideas for a future episode? We'd love to hear from you! Contact Cooperatively Speaking at podcast@eandi.org. This podcast is for informational purposes only. The views expressed in this podcast may not be those of the host(s) or E&I Cooperative Services.

Medline shows us how it's done with ill turntable antics and fantastic deep digs from Vic Upshaw, Fairuz, Leprechaun, Leo Acosta and Grupo Santa Cecilia. Plus poisonous Wu darts from Dabrye and Swollen Members, an underground classic from Hi-Tek and the "battle of the Burning Spears" with Néstor Álvarez and Woodfield Rd Allstars. View the full playlist for this show at https://www.wefunkradio.com/show/1241 Enjoying WEFUNK? Listen to all of our mixes at https://www.wefunkradio.com/shows/

In today's episode, we explore the fascinating world of nutrition essentials with a special focus on healthy oils and essential nutrients. Our esteemed guest, Udo Erasmus, is a pioneer in the field, known for founding Udo's Choice oil and authoring the influential book "Fats that Heal, Fats that Kill," which has sold over 250,000 copies. With a rich background in biochemistry, genetics, and biology, Udo shares his journey from a harrowing childhood during World War II to becoming a leading expert in health and nutrition. Learn More: https://udoerasmus.com/  

Soul Safari heads into the wild with rousing soul by Etta James and Rance Allen, reggae stylings from Gold Connection, French rap by Alliance Ethnik and surprise versions from Flipout and Deejay Irie. Plus peak indie goodness from Encore and Lightheaded, dusty grooves from French Chilean marvel Medline and supercharged funk reworks from U-Tern and Professor Groove. View the full playlist for this show at https://www.wefunkradio.com/show/1239 Enjoying WEFUNK? Listen to all of our mixes at https://www.wefunkradio.com/shows/

Pushback has likely stopped Mayor Brandon Johnson's proposed alcohol tax hike in its tracks. Crain's restaurants reporter Ally Marotti joins host Amy Guth to discuss that and more from Chicago's hospitality scene, including the wine world bracing for possible Trump tariffs.Plus: City panel OKs South Works quantum campus, Deere shares gain on optimism farm gloom will lift in 2025, Medline reportedly could raise $5B in a 2025 IPO and McDonald's targets choosy diners with value menu revamp.

Send us a textSLAS Scientific Director Lesley Mathews, Ph. D., speaks with several winners of our Tony B. Travel Award who presented at the SLAS Europe 2024 Conference and Exhibition.Congratulations to our winners!(Listed in interview order)Shitanshu Devrani, Ph.D. (University of Gothenburg)An Automated High-Throughput Platform for AI-Guided Development of Nanopore Membrane Biosensors and Real-time Edge Processing, Demonstrated with Wilson's Disease Sample VerificationLeticia Manen, Ph.D. (Bellvitge Biomedical Research Institute)Harnessing Drug Metabolites In Precision Medicine: Deeping into antineoplastic's major metabolites polypharmacologyJoel Sanchez Barea, Ph.D. Candidate (Incheon National University)Multiplexed detection of single-point mutations in human serum by integrating Surface Enhanced Raman Scattering with Polymerase Chain Reaction.What is the Tony B. Travel Award?This annual travel grant program provides funding for the SLAS International Conference and Exhibition and the SLAS Europe Conference and Exhibition for students, graduate students, post-doctoral associates, and junior faculty with less than four years in their first academic appointments.  Visit our Student Resources to learn more about these awards.Stay connected with SLASOnline at www.slas.orgFacebookTwitter @SLAS_OrgLinkedInInstagram @slas_orgYouTubeSLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.  For more information about SLAS, visit www.slas.org.SLAS publishes two peer-reviewed and MEDLINE-indexed scientific journals, SLAS Discovery and SLAS Technology. For more information about SLAS and its journals, visit slas.orgUpcoming SLAS Events: SLAS 2024 Data Sciences and AI Symposium November 12-13, 2024 Cambridge, MA, USA SLAS2025 International Conference and Exhibition January 25-29, 2025 San Diego, CA, USA SLAS Europe 2025 Conference and Exhibition 20-22 May 2025 Hamburg, Germany View the full events calendar

In this interview, Betsy speaks with Maxwell Cohen, the inventor and CEO of PEELAWAYS, founder of "Know Startups," and host of the podcast "Startup Brothers." Maxwell appeared on Shark Tank in Season 7, Episode 8. He discusses how he came up with the idea for PEELAWAYS, the first multi-layered, disposable, 100% waterproof fitted sheets designed for homes and institutions.The conversation highlights the challenges of regularly changing and washing sheets, and Betsy mentions how useful the product could have been for her husband, Matt.PEELAWAYS sheets come in various sizes, from crib to king, and have numerous benefits, including keeping users dry, reducing laundry, and providing a hygienic option for bedridden individuals. They're also great for travel, furniture protection, and car seats. Maxwell shares that PEELAWAYS are available through Medline, which distributes to various institutions and home care markets.Become a supporter of this podcast: https://www.spreaker.com/podcast/chatting-with-betsy--4211847/support.

Steve Grzanich has the business news of the day with the Wintrust Business Minute. Northfield-based Medline will use artificial intelligence to improve the resiliency of the health care supply chain. The company has announced a partnership with Microsoft and will use a new tool called Mpower. According to Crain’s, it’ll analyze customer and supplier data […]

You probably think a cucumber is a vegetable, right? But, according to scientists, it's actually a fruit. And it's a really, really cool fruit! Eating just one cucumber every day will result in numerous positive health changes and beauty benefits! Cucumbers might be low in calories, but they are extremely rich in minerals and vitamins. This fruit contains fiber, carbs, protein, vitamins C, K, and B, potassium, manganese, iron, zinc, riboflavin, and magnesium. But if you're used to peeling cucumbers, you'd better get rid of this habit! By peeling this fruit, you significantly decrease the amount of fiber, vitamins, and minerals that it contains. TIMESTAMPS: You'll get additional hydration 0:55 Cucumbers will supply you with necessary nutrients 1:54 You'll start to lose weight 2:44 You won't need any breath fresheners 3:57 Your blood sugar will decrease 4:36 You won't feel stressed anymore 5:15 Your hair and skin will be happy and healthy 5:43 You'll have a healthy heart 6:21 Cucumbers contain a lot of antioxidants 6:59 You won't have any complaints about your digestion 8:14 #cucumbers #healthydiet #beautybenefits Music by Epidemic Sound https://www.epidemicsound.com/ SUMMARY: - Since cucumbers contain so much water, they're great at cleansing your body of harmful toxins. As a result, your immune system will become stronger, you'll feel more energetic, and your physical performance will improve. - Being a perfect source of B vitamins, cucumbers can effectively help you if you're suffering from a hangover. Even if you don't get rid of this unpleasant condition completely, its intensity will decrease noticeably. - A medium-sized cucumber contains only 16 to 20 calories. This means that you can eat as many cucumbers as you want, get all the necessary nutrients and elements, and it won't result in any weight gain. - Cucumbers are good for more than your general well-being. They can also have an immediate positive effect if you have problems with bad breath as they are a natural breath freshener. - According to several studies that can be found in the MEDLINE database, cucumbers have the ability to lower and control blood sugar. - There are different B vitamins in cucumbers: B1, B5, and B7 (or biotin). These vitamins are famous for their ability to reduce anxiety and cushion the negative effects of stress. - Cucumbers are rich in silica, a vital component for the development of healthy and strong connective tissues. Silica can also improve the condition of your skin by making it brighter and healthier. - One of the minerals contained in cucumbers is potassium. Your body functions properly only if there's the necessary balance of this mineral inside and outside your cells. - Antioxidants fight the free radicals that damage your cells and their genetic material by causing the oxidation process. - Cucumbers contain a lot of water, thus promoting hydration. Eating them regularly can prevent constipation. Subscribe to Bright Side : https://goo.gl/rQTJZz ---------------------------------------------------------------------------------------- Our Social Media: Facebook:   / brightside   Instagram:   / brightgram   5-Minute Crafts Youtube: https://www.goo.gl/8JVmuC ---------------------------------------------------------------------------------------- For more videos and articles visit: http://www.brightside.me/ Learn more about your ad choices. Visit megaphone.fm/adchoices

My guest this week is Greg Christopherson, Vice President, Medical Affairs at Medline who discusses how to effectively build a modern medical affairs organization. Learn more about…

The humble towel. If you're reading this in an SPD, you're probably less than 6 feet from a towel this very moment, and yet how often have you ever really stopped to think about what that little piece of fabric actually does? On this week's episode of Beyond Clean, "The Little Things that Make a Big Difference,” we talk to Tory Teakell, Clinical Solutions Manager for Medline, about all things surgical towels! From linting concerns to color coding, and more – we've "woven" it all into this important conversation about a little piece of fabric that has big implications for surgical care. Get ready to roll up the volume and soak up all the clinical insights during today's show! We can't wait to have you tune in! Season 25 of Beyond Clean releases under the 1 Episode = 1 CE delivery model. After finishing this interview, earn your 1 CE credit immediately by passing the short quiz linked below each week. Visit our CE Credit Hub at beyondcleanmedia.com/ce-credit-hub to access this quiz and over 350 other free CE credits.  #BeyondClean #SterileProcessing #WeFightDirty

Deja Nair v. Medline Industries, LP

Seth Casden is the Founder and CEO of Hologenix, a material science company known for its innovative product, CELLIANT, designed to amplify human potential and overall health. Hologenix's innovative textiles, which harness the power of infrared for enhanced performance and health, have led to partnerships with renowned brands such as AEON, Bear, Decathlon, DFND, Medline, and Under Armour. Seth has a degree from Pepperdine University and frequently speaks at industry conferences. Under his leadership, Hologenix has been named to the Inc. 5000 list of the fastest-growing privately held companies in the US for three consecutive years, showcasing his ability to drive impressive growth and innovation. In this episode… Have you ever wondered how to turn innovation into profit and sell it to other companies? In a constantly transforming economy, excelling with innovative technological solutions is crucial. Could there be an intersection of technology and the textile industry? Seth Casden faced these questions head-on when he helped develop CELLIANT, a performance textile designed to improve circulation through infrared energy. He explains how his company created a textile embedded with infrared-emitting minerals that enhance circulation and aid recovery. Despite the initial challenges, including skepticism from major brands like Under Armour, his team substantiated their claims through rigorous scientific studies. Seth emphasizes the importance of long-term vision and patience, investing in studies and product development that may take years to bear fruit but ultimately establish credibility and market demand. Tune in to this episode of the Smart Business Revolution Podcast as John Corcoran interviews Seth Casden, Founder and CEO of Hologenix, about the intersection of textiles and technology. They discuss how working at a law firm laid the foundation for Hologenix, the impact of private equity experience on company strategy, and overcoming challenges to partner with major brands. He also emphasized the importance of long-term vision and scientific validation.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.CDRH Director Jeff Shuren is set to step down after 15 years, with Michelle Tarver serving as acting director of the FDA's medical devices unit. Boston Scientific predicts strong growth for Farapulse following a successful launch. The top 5 medtech deals in the first half of 2024 include Johnson & Johnson's $13.1 billion takeover of Shockwave Medical. ICU Medical is closing a Minnesota facility and cutting 83 jobs, while Cook Medical plans to sell its reproductive health business to a private equity firm. Medline is exploring an IPO in 2025, Magenta securing $105 million for trials of the world's smallest heart pump, and robotic aid improving balance and gait in children with cerebral palsy.Transitioning to healthcare news, HCA reported $17.5 billion in revenue in the second quarter and raised its full-year guidance. Humana's Centerwell plans to open 23 primary care clinics at Walmart stores. Maternal health quality varies by state, with states with more restrictive abortion bans having fewer maternal health providers and higher maternal death rates. Pharmacy benefit managers, including CVS Caremark, Optum Rx, and Express Scripts, faced scrutiny from Congress over drug pricing policies. AI is being used to transform unstructured patient data into structured reports in healthcare systems.Moving on to updates in pharmaceuticals, Pfizer's hemophilia gene therapy met its late-stage study goal, but questions remain about the long-term potential of hemophilia treatments. Biogen's tremor drug, Sage-324, failed a key trial, and the FDA's medical device chief, Shuren, is stepping down after 15 years. Novartis is investing in bispecifics for cancer, while Autobahn raised $100 million for neuropsych drugs. Bob Langer steps down from Moderna's board, and PBMs are facing bipartisan scrutiny over drug pricing policies.In the biopharma sector, Biogen and Sage Therapeutics have discontinued a phase II trial for an investigational neuroactive steroid for essential tremor after it failed to significantly improve upper limb tremors. Pfizer's gene therapy for hemophilia A has shown positive results in a phase III trial. The FDA has raised concerns about potential overtreatment with AstraZeneca's Imfinzi for resectable non-small cell lung cancer. There is speculation about whether Merck should buy out Moderna to strengthen their partnership on Keytruda-cancer vaccine.Lastly, in marketing news, Google's ad revenue remains strong despite transitions in technology, with AI implementations and cookie changes. Albertsons' retail media business is incorporating AI and in-store technology to improve operations. Coca-Cola and Delta are 'olympicizing' their campaigns with NBCUniversal, as advertisers spend over $1.2 billion for the Olympics. Google has become the official search AI partner of Team USA, leveraging its products for NBCUniversal's Olympics coverage.The marketing landscape is evolving with a focus on technology, data-driven strategies, and partnerships between brands and media companies like NBCUniversal and Google.

Crain's residential real estate reporter Dennis Rodkin talks with host Amy Guth about top stories from the local housing market, including a historic Prairie-style kindergarten-turned-home for sale in Brookfield.Plus: Chicago's donor class opens its pockets for Harris; Medline exploring IPO, with possible valuation of $50 billion; Cboe to offer traders another way to hedge S&P 500 swings; and Intersect Illinois hires physicist to recruit quantum companies.

On the latest episode of Planning Aces three dynamic CFOs—Robert Cornella (RNDC), Karen Williams (American Express Global Business Travel), and Tony Querciagrossa (Pinstripes)—share a menu of FP&A insights and experiences. Robert Cornella emphasized the importance of understanding value chain economics and achieving operational harmony within complex mergers. His experience at Coca-Cola highlighted the necessity of predictable revenue streams and balanced incentives for long-term investment. Karen Williams brought a fresh perspective on utilizing data. She stressed the need for a proactive approach in gathering and analyzing diverse data sources, alongside encouraging self-sufficiency within teams using different technology tools. Her focus on customer feedback underscores the value of real-time insights in shaping business strategies. Tony Querciagrossa reflected on his entrepreneurial journey, underlining the benefits of working in smaller companies where exposure to various business aspects is inevitable. His pivotal moment at Medline illustrated the significance of aligning financial support with organizational needs, fostering a collaborative environment to solve broader business problems. Hosts, Sweeney and Knowles, highlight the shared themes of data curiosity, the evolving role of finance in operational decisions, and the importance of cross-functional competencies. 

Writer Ben Edlund discusses balancing drama with humor and trying to be gross. We are lucky to have a second interview with cupid himself, Lex Medline. He had to wear his own wardrobe for the shoot. Learn more about your ad choices. Visit megaphone.fm/adchoices

An estimated 40% of expenditure in the supply chain goes to waste. CEO Luka Yancopoulos explains to Jim Cagliostro how Grapevine Technology aims to put the power back into the hands of hospitals.   Episode Introduction  Luka explains how Grapevine can help hospitals save up to 80% on a single line item, how even small healthcare businesses spend six figure sums on the supply chain each year, and how to frame the reality of years of overspending to his clients. He also reveals three key ways that hospitals can lower the expense of their vendor management.      Show Topics   The power of building networks Supplies are a huge expense in healthcare Up to 80% of spend may be waste Connecting the source of supply to the end user Framing harsh truths on expenditure Seeing value every step of the way Leadership tip: deliver solutions to real problems 03:12 The power of building networks Luka said Grapevine can help its clients to save 70-80% on a single line item.  ‘'So Grapevine is working to make it very easy to basically manage your existing network. We've got healthcare businesses. They usually come to us, and they've worked with a handful of suppliers over the years. They think of each of these suppliers as their supplier for blank, fill in the blank, and Grapevine rewrites that. We think they're all your suppliers, they're all your network. Every time you add an item to cart from one of them, let's make sure it's the best price and that your other suppliers that you already trust and know don't have the same exact product at a cheaper price. Oftentimes, they do. We've basically redirected spend from one major distributor to another major distributor, saving the customer or the healthcare business 70%-80% on a single line item. The thing like a Becton Dickinson or a BD catheter or infusion pump or something they buy, and they have a bad habit of buying it from the wrong guy. So we basically let them link all their suppliers with the click of a button to a single screen, read in their current offerings, and tell them where to redirect their spend, acting as a traffic cop if needed.''   05:14 Supplies are a huge expense in healthcare Luka explained that even small healthcare businesses are spending six figure sums on supplies every year.  ‘'Certain medical specialties get hit harder than others. If you're performing surgery, obviously, you're burning through a lot of supplies, you're using anesthesia, you're using all sorts of things that maybe your average urgent care clinic won't need. So we focus on specific specialties that have a high consumption rate of important and expensive technologies, things like oncology, dermatology, surgery, these sorts of things. Even a small healthcare business is spending six, seven figures on medical supplies and pharmaceuticals, like, a customer that comes to mind, a family-owned dermatology practice in upstate New York, and Rochester, New York is spending $200,000 a year pre-Grapevine on medical supplies. So like the instruments and whatnot, they're using sutures and implants and this and that, and then they're spending another million a year on injectables. Things like lidocaine, fillers, and different sorts of things of that realm.''   08:38 Up to 80% of spend may be waste  Luka explained why a single supplier can't offer hospitals the lowest price for every item.  ‘'I think that, in some cases, it's as much as 80% of the spend on supply is fruitless and extraneous. As far as what makes up those inefficiencies, there's a number of things. There's a classic idea that I am a strong believer of, that no one person or entity can be the best at everything. So even if you're comparing suppliers of the same business model, these large distributors, we could talk like McKesson, Henry Schein, Medline, the list goes on and on. Every one of those has built supply chains like warehouse fulfillment, shipping teams, customer service, et cetera, tailored around a specific core competency or level of products. So not one of those suppliers is going to be able to offer you the 5,000 SKUs or different item numbers that you need, all of the lowest price. That's naive. The way this world works is helping specialists, people that have specific skill sets, work together to serve a singular end goal.''   10:24 Connecting the source of supply to the end user Luka said simplifying the supply chain is key to reducing costs.  ‘'I understand that when I'm buying it from a reseller, it needed to get in the hands of the reseller. That means it needed to get shipped there. That is a cost. Costs get built on the customer service, the labor. It all gets built into the price that hospitals are paying. By working with these downstream distribution companies that are, in some cases, 200 years old, you're just taking on additional costs. So if we can disintermediate supply chains when possible, connect source to end user as much as possible. You make things overall much more efficient. Then the third and really important major point, just to exemplify the inefficiencies and the lack of belief I have in these major distributors, is, you've got these distributors that people still buy everything they need from. These are the same companies that were selling cocaine pills to pregnant women in the late 1800s and arsenic pills for patient treatment and temperature up until the mid-1900s.''   13:33 Framing harsh truths on expenditure Luka said understanding the extent of potential cost savings can be a shock to hospital executives.  ‘'People are definitely surprised, and honestly, I need to figure out a better way to frame sometimes exposing harsh truths to our customers because we've had people... When you find out that something bad's been going on for a long time and you're the victim of that bad thing, it does not feel good. We've got customers that are hurt by that. They don't blame us, but I wish we could deliver that more as an opportunity to win as opposed to an exposé of historic losses. I think you could do that with the right framing, with the right user interfaces, but it's something that we're not doing the best job of now, just packaging that and making it a digestible change for them. But yeah, people are shocked when they're working with, let's just say, even two distributors. They're working with... We've talked about the names already, so I won't name them here, but one 200-year-old company and they have another 100-year-old company that they've worked with, and when they add to cart for the first time on Grapevine that same IV catheter that they've purchased thousands of times, that they've spent literally millions of dollars on over the last couple of years, that one item number, and they add it to cart and it says, "But wait, you could buy the same exact item from the other supplier that you already trust and know for 70% cheaper." That happens. They feel a level of frustration, and rightfully so.''    22:47 Seeing value every step of the way  Luka said that hospitals need to be able to see the win and the reason when they're stepping out of their comfort zone.  ‘'So work with your existing suppliers, and you're going to save a lot of money by having them on one screen and us alerting you, and there's a cheaper alternative. Once you've done that, then, "Hey, why don't we introduce you to this broad network of new suppliers that we know, that we've vetted, that we trust?" And you can connect them and start subbing in not exact matches from your trusted network, but new suppliers or specialists that can add way more value, exponential value, and achieve even more savings. That's why we could deliver this all in month one as a 60%, 70% savings, but it's not palatable. People would rather get month one of halfway there, big win, see their wins and their hard work paying off, and see the value of what they're doing every step of the way. Every time we make them do something outside of their comfort zone, they need to be able to see the win and the reason. If it ties back to financial savings, that's part of it. For the people that actually shop, we're putting things into one screen, and that's a part of it. They don't need to flip between tabs and windows anymore. So showing what we do and showing why it's helpful to them every step along the way to mitigate the pain of adopting a new solution is a big part of our philosophy here.''   25:19 Leadership tip: deliver real solutions for real problems  Luka said solving the biggest problems for your target customers is the way to unlock real value as a business.  ‘‘…So I think if you are following the white rabbit of real problems for real people, real struggles, and you constantly and iteratively try to come up with smarter and better solutions to solve those pain points, and once you do look for new problems, the next biggest problem they're facing, and continuously deliver real solutions based on those problems, I think that's the key to financial success as a business, is make yourself important, make yourself valuable, make yourself the solver of the biggest problems for your target customers, and that's the way that you unlock real value as a business and the money, the revenue, the whatever it comes all from that. If you're not important to solving someone's real problem, mending someone's real problems, then you shouldn't play the game of business in the world that we live in.'' Connect with Lisa Miller on LinkedIn Connect with Jim Cagliostro on LinkedIn Connect with Luka Yancopoulos on LinkedIn    Check out VIE Healthcare and SpendMend    You'll also hear:    How Grapevine is putting the power back in the hands of healthcare providers: ‘'We do that by showing doctors what they should be paying for the supplies that they use on a regular basis. We make it incredibly easy to achieve savings of more than 50% on their healthcare, medical supply, and even drug, pharmaceutical spend.''   Helping healthcare organizations to shop smarter: The hospital that saved 40% in one month: ‘'We've got a public company that uses Grapevine. They have 80 locations. They're in the oncology space. They went from spending $400,000 a month on supplies down to $250,000 in their first month, which was January 2024. So they are down 40% in the first month. There's a lot more work for us to do there. I think we can get them down to close to 80%.'' Recognizing that every hospital has unique needs: ‘'So yes, we need to have standardization. We need to have the best practice, best ways of doing things, but this hospital, this large health system in New York has different needs than a rural hospital out in Kansas or wherever it may be. So meeting those needs is going to look different. So we need to find ways to do that in order to minimize those inefficiencies.'' Putting all of your data into one screen is the first step to reducing waste: ‘'If you're managing 100 different suppliers, and that means you have a person or maybe dozens of people or hundreds of people that log into one screen and then they are pulling up listings that look totally different, and then putting another window up and looking at it on the other screen and then trying to do that across 12, you're hopeless at that point. You need to have all of your options in one place. ‘'   What To Do Next:   Subscribe to The Economics of Healthcare and receive a special report on 15 Effective Cost Savings Strategies.   There are three ways to work with VIE Healthcare:   Benchmark a vendor contract – either an existing contract or a new agreement. We can support your team with their cost savings initiatives to add resources and expertise. We set a bold cost savings goal and work together to achieve it.  VIE can perform a cost savings opportunity assessment. We dig deep into all of your spend and uncover unique areas of cost savings.  If you are interested in learning more, the quickest way to get your questions answered is to speak with Lisa Miller at lmiller@spendmend.com or directly at 732-319-5700.  

Norton Healthcare's Plugged in to Nursing is the podcast that celebrates and informs the profession of nursing. Title: Serving All, Norton Healthcare Medical Librarians Summary: Did you know Norton Healthcare has its own medical librarians, medical journal, and archivist? In February's episode of Plugged In to Nursing, hear Adriana Barnes Clizbe, RN, Beth Johnson, system medical librarian, and Cece Railey, system medical librarian, discuss the many educational resources Norton Healthcare offers through its medical librarian team. Learn whom the librarians support, expectations when literature requests are placed, and how to connect with resources in-personand virtually. As Cece shares, the role of a librarian is similar to the work of an investigator; our librarians are here to help us gather information so we can provide the best care to all those we serve! Speakers: Adriana Barnes Clizbe, RN Norton Brownsboro Hospital Beth Johnson, MSLS, MSET System Medical Librarian Cece Railey, MSLS, AHIP-D, MPH  System Medical Librarian   Helpful Show Notes: ‘VML' is Norton Healthcare's Virtual Medical Library ‘Nsite' is Norton Healthcare's intranet ‘Epic' is Norton Healthcare's internal electronic medical record platform PubMed: https://pubmed.ncbi.nlm.nih.gov/ CINAHL: https://www.ebsco.com/products/research-databases/cinahl-database ClinicalKey: https://www.clinicalkey.com/#!/ Medline: https://medlineplus.gov/ UptoDate: https://www.wolterskluwer.com/en/solutions/uptodate DynaMed: https://www.dynamed.com/ ‘PDR' is the Physician's Desk Reference: https://www.pdr.net/ library@nortonhealthcare.org ‘RSV' is respiratory syncytial virus Shirley.Harmon@nortonhealthcare.org   About Norton Healthcare's Center for Nursing Practice Norton Healthcare's Center for Nursing Practice is responsible for readying student nurses for practice and transitioning new graduate nurses into practice.  Our team is committed to serving the profession of nursing, meeting people where they are and taking them to where they want to be. Contact Information:  PluggedInToNursing@nortonhealthcare.org

Send us a Text Message.As your host, Jamie Vaughn, I share a connection with this episode's special guest, Dr. Ramon Garza of Dr. Garza Plastic Surgery, hailing from the heart of Texas with a scalpel as sharp as his insights into breast reconstruction. His mastery of microsurgery and compassionate approach to patient care echo my own philosophy, one deeply rooted in empathy and the shared journey of resilience in the breast cancer community. Together we discuss the emotional intricacies of the doctor-patient relationship, revealing how modern medicine is embracing shared decision-making and the transformative power of being well-informed.Dr. Garza debunks the myths surrounding the DIEP flap procedure, laying out the facts for anyone considering this path to recovery. Our conversation navigates through the challenges and considerations of radiation's impact on reconstruction, stressing the importance of strategic planning and patient-specific approaches to phase 2 surgeries. Rounding out this episode, we tackle the complexities surrounding Silicone Implant Illness and the nuanced realities of breast reconstruction versus cosmetic surgery. I share a bit of my own path, including my upcoming journey to San Antonio for nipple tattoos with Perky, a testament to the sense of community and shared experiences that bind us.  Contact Dr. Garza: Dr. Garza on Instagram  Dr. Garza Plastic Surgery Resources: American Society of Plastic Surgeons PubMed is a free search engine accessing primarily the MEDLINE database of references and abstracts   Are you loving the Test Those Breasts! Podcast? You can show your support by donating to the Test Those Breasts Nonprofit @ https://testthosebreasts.org/donate/ Where to find Jamie:Instagram LinkedIn TikTok Test Those Breasts Facebook Group LinkTree Jamie Vaughn in the News! Thanks for listening! I would appreciate your rating and review where you listen to podcasts!I am not a doctor and not all information in this podcast comes from qualified healthcare providers, therefore may not constitute medical advice. For personalized medical advice, you should reach out to one of the qualified healthcare providers interviewed on this podcast and/or seek medical advice from your own providers .

Steve Grzanich has the business news of the day with the Wintrust Business Minute. Northfield-based Medline has completed its acquisition of United Medco, and the company says it marks a significant milestone in the growth of Medline’s health plans business. Medline is a manufacturer and supplier of medical supplies and solutions. United Medco provides supplemental […]

Episode #77 featuring Tanja Zaric, Senior Manager at Medline Industries. Medline is a healthcare company–a manufacturer, distributor and so much more, doing business in more than 125 countries and territories around the world. In a complex healthcare world, Medline strives to help their customers achieve both clinical and financial success. Listen to Tanja Zaric talk about how Medline uses AlexAnndra Ontra's company Shufflrr at Medlibe and learn how Shufflrr can also help your company manage content through structured storytelling. Visit www.Shufflrr.com for Presentation Management

This is a re release of one of our most listened to episodes! Be sure you don't miss it this time around!It's common for people to ask what they can do to prepare themselves for labor and birth. On today's episode, we will talk about it all…exercises to do, foods to eat, things to drink, and practitioners to see!Mentioned articles:EBB 216 - The Evidence on Prenatal Perineal Massage for Preventing Tears in Childbirth with Dr. Rebecca Dekker - Evidence Based Birth®EBB 128 - Inducing Labor with Castor Oil and Dates - Evidence Based Birth®February 9, 2021, systematic review published in BMC Complementary Medicine and Therapies evaluated 6 databases (CINAHL, MEDLINE, Cochrane Library, Scopus, Web of Science Core Collection, and AMED database)Mentioned Instragram people to follow:MamasteFit: Gina & Roxanne (@mamastefit) • Instagram photos and videosPUSH fitness (@pushfitmom) • Instagram photos and videosPlease feel free to reach out to us with any recommendations for show episode ideas. If you'd like to be a guest, email us with some information about yourself and what type of podcast you'd like to record together. Thank you for all of your support and don't forget to follow and review our podcast, Birth, Baby!Instagram: @‌BirthBabyPodcastEmail: BirthBabyPodcast@gmail.comWebsite: https://birthbabypodcast.transistor.fm/Intro and Outro music by Longing for Orpheus. You can find them on Spotify!

Join Lisa from Medline for an exclusive peek into the cutting-edge world of respiratory care! Discover Medline's groundbreaking initiatives and Lisa's expertise firsthand. Don't miss this chance to explore the future of healthcare with industry leaders!Send us a text

Dr. Omkar Desai, from the Department of Surgery at Case Western Reserve University and University Hospitals Cleveland Medical Center, describes a research perspective he co-authored with Dr. Rui Wang that was published by Oncotarget in Volume 14, entitled, “HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.” DOI - https://doi.org/10.18632/oncotarget.28421 Correspondence to - Rui Wang - rxw517@case.edu Author video - https://www.youtube.com/watch?v=3-02jt7-MW8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28421 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - HER3, colorectal, pancreatic cancer, metastasis, microenvironment About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

How we access medical information and where it comes from is all important. It has changed hugely in the last 50 years and in this episode I look at how and why that has happened and also the future.Change in news sources: https://pressgazette.co.uk/media-audience-and-business-data/most-popular-news-sources-uk-tiktok-ofcom-news-consumption-survey/Cochrane: https://www.cochrane.org/Medline (electronic library): https://medlineplus.gov/Dipex: https://dipexcharity.org/about-us/Electronic records: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5171496/Medical knowledge doubles every 73 days: https://www.nature.com/articles/s43856-021-00003-5YouTube Health: https://health.youtube/Prof Kausik Ray's meta-analysis (a study of studies): https://bjcardio.co.uk/2012/03/aspirin-in-primary-prevention-new-meta-analysis/Statins - one view: https://www.bmj.com/content/348/bmj.g3458/rr/761453Reliable health info sources (in my opinion): https://www.healthline.com/ Hosted on Acast. See acast.com/privacy for more information.

Luká Yancopoulos is CEO of Grapevine Technologies, a COVID-inspired company determined to increase resilience in the supply chain for healthcare supplies. Disrupting the current network of manufacturers, importers, and distributors, Grapevine is connecting suppliers directly to end users. They aim to build a more resilient network of suppliers, eliminate waste and unnecessary costs for medical providers, and reduce patient charges.      Luká explains, "Not a lot has changed in the healthcare space regarding logistics and supply chain in my lifetime. So, getting things to change and getting things to budge is definitely difficult in nature. But our primary business innovation is that we seamlessly connect a data-driven network of primary suppliers directly to healthcare practices." "When I say that Grapevine is connecting this data-driven network of primary suppliers, we're using the data made publicly available by the United States government to find actual importers or manufacturers of the medical supplies and find the companies that sell to McKesson, Henry Schein, Cardinal Health, and Medline. And we basically onboard those primary suppliers, those importers, upstream of the middleman, McKesson, and these big dinosaur distributors. And we connect those importers directly to end users." "There's a lot that incurs additional costs between the importer and the end user when they purchase from McKesson. They have to move it to McKesson's warehouse. They then pay the McKesson labor staff. They pay the account manager. And by bypassing the middleman, you bypass with him his inefficiencies, his markups. And at Grapevine, we can offer the same products that these healthcare practices already buy at an average of 62% lower prices, which is a significant saving that can be carried forward to patients and reduce the financial burden of healthcare costs."  #GrapevineTechnologies #SupplyChain #MedicalSupplies #MedicalDevices #Healthcare #CostReduction #SupplyShortages go-grapevine.com Download the transcript here

Luká Yancopoulos is CEO of Grapevine Technologies, a COVID-inspired company determined to increase resilience in the supply chain for healthcare supplies. Disrupting the current network of manufacturers, importers, and distributors, Grapevine is connecting suppliers directly to end users. They aim to build a more resilient network of suppliers, eliminate waste and unnecessary costs for medical providers, and reduce patient charges.      Luká explains, "Not a lot has changed in the healthcare space regarding logistics and supply chain in my lifetime. So, getting things to change and getting things to budge is definitely difficult in nature. But our primary business innovation is that we seamlessly connect a data-driven network of primary suppliers directly to healthcare practices." "When I say that Grapevine is connecting this data-driven network of primary suppliers, we're using the data made publicly available by the United States government to find actual importers or manufacturers of the medical supplies and find the companies that sell to McKesson, Henry Schein, Cardinal Health, and Medline. And we basically onboard those primary suppliers, those importers, upstream of the middleman, McKesson, and these big dinosaur distributors. And we connect those importers directly to end users." "There's a lot that incurs additional costs between the importer and the end user when they purchase from McKesson. They have to move it to McKesson's warehouse. They then pay the McKesson labor staff. They pay the account manager. And by bypassing the middleman, you bypass with him his inefficiencies, his markups. And at Grapevine, we can offer the same products that these healthcare practices already buy at an average of 62% lower prices, which is a significant saving that can be carried forward to patients and reduce the financial burden of healthcare costs."  #GrapevineTechnologies #SupplyChain #MedicalSupplies #MedicalDevices #Healthcare #CostReduction #SupplyShortages go-grapevine.com Listen to the podcast here

Welcome to the latest episode of Health with Hashimoto's where we uncover an amazing test that can reveal your Hashimoto's risk a whopping 15 years before symptoms arise. Intrigued? Well, I've got all the details for you. Did you know that your thyroid antibodies can actually appear on lab work long before you experience any symptoms or even receive a diagnosis? It's true! In fact, these antibodies are often one of the earliest indicators of Hashimoto's, yet they are rarely checked. Join me as we dive into the world of thyroid antibodies, learn how to test for them, interpret the results, and most importantly, discover how this valuable information can help you achieve better health.   RELATED EPISODES 009 // Vitamin D & Autoimmune Disease https://healthwithhashimotos.com/009-vitamin-d/ Vitamin D study: https://pubmed.ncbi.nlm.nih.gov/31071734/ Medline thyroid antibodies article: https://medlineplus.gov/lab-tests/thyroid-antibodies/   SCHEDULE A COACHING SESSION: Hashimoto's Health Session https://healthwithhashimotos.com/book-now/   FREE DOWNLOAD: Hashimoto's 101 is your free guide to understanding Hashimoto's thyroiditis so that you can create a path to health. https://healthwithhashimotos.com/guide/    About This Podcast and Esther: This is the Health with Hashimoto's podcast where exhausted women with Hashimoto's discover a true, simple, and sustainable path to whole health.   Hi! I am your host Esther Yunkin. I am a registered nurse with over 20 years of experience.   I grew fed up in the emergency department, where I saw people get short-term bandaids to chronic problems, so I went back to school for holistic health.   Now I help women with Hashimoto's thyroiditis discover simple and sustainable solutions to improve their energy without getting overwhelmed.   This podcast is for informational and educational purposes. Please discuss any questions or concerns with your healthcare professional.   CONNECT WITH ESTHER: Website: https://healthwithhashimotos.com Connect on Telegram @Esther_Yunkin Instagram @EstherY.RN https://www.instagram.com/esthery.rn/

It's common for people to ask what they can do to prepare themselves for labor and birth. On today's episode, we will talk about it all…exercises to do, foods to eat, things to drink, and practitioners to see!SummaryIn this episode, Ciarra and Samantha discuss how to prepare for labor and birth. They emphasize the importance of education, knowing your options, and taking a well-rounded childbirth class. They also talk about the benefits of exercise during pregnancy, including walking, prenatal yoga, and strength exercises. The hosts highlight the significance of nutrition, such as consuming high protein and high fiber foods, and getting essential vitamins and minerals. They also stress the importance of staying hydrated with water. Overall, the episode provides valuable information and tips for preparing for labor and birth. In this episode, the hosts discuss various methods that can help prepare the body for labor, including drinking red raspberry leaf tea, eating dates, and practicing perineal massage. They also touch on the benefits of chiropractic care, pelvic floor therapy, and acupuncture. While some of these methods have limited scientific evidence, they emphasize the importance of listening to your body and finding what works best for you. They also acknowledge that not everyone has access to or can afford these methods, and suggest alternative options like spinning babies exercises and self-performed perineal massage.TakeawaysTake a well-rounded childbirth class to learn about your options for labor and birth.Engage in regular exercise during pregnancy to build stamina and strength.Focus on nutrition by consuming high protein and high fiber foods and getting essential vitamins and minerals.Stay hydrated with water and limit caffeine intake.Be in tune with your body and listen to its needs throughout pregnancy. Drinking red raspberry leaf tea, eating dates, and practicing perineal massage are thought to help prepare the body for labor, although the scientific evidence is limited.Chiropractic care, pelvic floor therapy, and acupuncture can also be beneficial in preparing the body for labor.It's important to listen to your body and find what works best for you, as not all methods may be effective for everyone.Alternative options like spinning babies exercises and self-performed perineal massage can be helpful for those who cannot access or afford other methods.Mentioned articles:EBB 216 - The Evidence on Prenatal Perineal Massage for Preventing Tears in Childbirth with Dr. Rebecca Dekker - Evidence Based Birth®EBB 128 - Inducing Labor with Castor Oil and Dates - Evidence Based Birth®February 9, 2021, systematic review published in BMC Complementary Medicine and Therapies evaluated 6 databases (CINAHL, MEDLINE, Cochrane Library, Scopus, Web of Science Core Collection, and AMED database)Mentioned Instragram people to follow:MamasteFit: Gina & Roxanne (@mamastefit) • Instagram photos and videosPUSH fitness (@pushfitmom) • Instagram photos and videosPlease feel free to reach out to us with any recommendations for show episode ideas. If you'd like to be a guest, email us with some information about yourself and what type of podcast you'd like to record together. Thank you for all of your support and don't forget to follow and review our podcast, Birth, Baby!Instagram: @‌BirthBabyPodcastEmail: BirthBabyPodcast@gmail.comWebsite: https://birthbabypodcast.transistor.fm/Intro and Outro music by Longing for Orpheus. You can find them on Spotify! (00:00) - Preparing for Labor and Birth: Education and Options (07:50) - Exercise During Pregnancy: Building Stamina and Strength (11:54) - Nutrition During Pregnancy: High Protein and High Fiber Foods (24:55) - Being in Tune with Your Body: Listening to its Needs (30:51) - Preparing the Body for Labor: Red Raspberry Leaf Tea, Dates, and Perineal Massage (33:02) - Additional Methods for Labor Preparation: Chiropractic Care, Pelvic Floor Therapy, and Acupuncture (44:10) - Perineal Massage and Scar Tissue (50:52) - Balancing the Body: Chiropractic Care, Pelvic Floor Therapy, and Acupuncture (58:23) - Alternative Options for Labor Preparation: Spinning Babies Exercises and Self-Performed Perineal Massage

A new research paper was published in Oncotarget's Volume 14 on July 1, 2023, entitled, “Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin.” Members of the rat sarcoma viral oncogene (RAS) subfamily KRAS are frequently mutated oncogenes in human cancers and have been identified in pancreatic ductal, colorectal, and lung adenocarcinomas. Recently, two drugs that specifically target KRAS G12C, sotorasib (Lumakras™) and adagrasib (Krazati™), have received accelerated approval by the FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy. These drugs are the first RAS GTPase family inhibitors to be approved for clinical use, representing a major breakthrough in the field of precision oncology. In this new study, researchers Joel Ohana, Uziel Sandler, Orly Devary, and Yoram Devary from Immune System Key (ISK) and Jerusalem College of Technology show that a derivative of the hormone peptide Tumor Cell Apoptosis Factor (TCApF), Nerofe™ (dTCApFs), in combination with Doxorubicin (DOX) substantially reduces viability of tumor cells. “The objective of the present study was to investigate the synergistic effect of the combination of Nerofe and DOX in colorectal cancer and its underlying mechanism.” It was observed that the combination of Nerofe and DOX downregulated KRAS signaling via miR217 upregulation, resulting in enhanced apoptosis of tumor cells. In addition, the combination of Nerofe and DOX also resulted in activation of the immune system against tumor cells, manifested by an increase in the immunostimulatory cytokines IL-2 and IFN-γ as well as the recruitment of NK cells and M1 macrophages to the tumor site. “In conclusion, we demonstrated that the combination of Nerofe and DOX exerts a synergistic effect during mCRC treatment, which could stem from several independent and complementary mechanisms of action.” DOI - https://doi.org/10.18632/oncotarget.28467 Correspondence to - Yoram Devary - ydevary@immunesk.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28467 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - Colorectal cancer, KRAS, apoptosis, hormone peptide, endoplasmic reticulum stress About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “ERβ as a mediator of estrogen signaling in inflammatory breast cancer.” In this new editorial, researchers Harika Nagandla and Christoforos Thomas from Houston Methodist Neal Cancer Center discuss inflammatory breast cancer (IBC)—a rare and aggressive form of breast cancer which accounts for 2–4% of all new breast cancer cases detected in the United States. Even with the application of standard multi-modality treatment approach that incorporates neoadjuvant chemotherapy, radiation and surgery, the 5-year survival rate for IBC is only about 40–50%. Breast cancer can be typically stratified into different types based on the presence of molecular drivers such estrogen receptor (ERα), progesterone receptor (PR) or human epidermal growth factor receptor 2 (HER2), which inform the treatment choice. For IBC, there is a substantially higher incidence of ERα negativity compared with other forms of breast cancer that can reach up to 60%. A specific targetable driver signaling pathway has not been identified so far. About one in three patients already have distant metastasis at the time of diagnosis, contributing to the aggressiveness and poor outcomes associated with IBC. Despite the absence of ERα from the majority of IBC tumors, estrogen signaling has been implicated in progression of the disease through ERα-independent pathways. ERβ is a ligand activated transcription factor that mediates effects of estrogen, along with ERα in different tissues during growth and development by regulating transcription of target genes. Tumor suppressive effects of ERβ have been documented in diverse cancer types such as thyroid, kidney, prostate, glioblastoma, ovarian and breast cancer. “The work from our group [6] establishes ERβ as a tumor suppressor in IBC by demonstrating its strong antimetastatic activity in preclinical models of the disease and delineating the mechanism of action.” DOI - https://doi.org/10.18632/oncotarget.28425 Correspondence to - Christoforos Thomas - cthomas3@houstonmethodist.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28425 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - inflammatory breast cancer, IBC, ERβ, metastasis, actin based cell migration About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

On the bright side, polo-like kinase 1 (PLK1) is considered a master regulator of the ever-important cell cycle. On the dark side, PLK1 expression (at both the mRNA and protein level) has shown to be upregulated in tumor cells, suggesting that PLK1 may also contribute to tumorigenesis. Despite this direct association, researchers studying the role of PLK1 in cancer have encountered a problem: a lack of appropriate animal models for experimentation. “Even though studies have suggested that PLK1 contributes to tumorigenesis, the ability of PLK1 to drive oncogenic transformation on its own in vivo was still questionable due to a lack of sophisticated animal models for experimentation [18, 19].” This problem may have been solved in 2021. In a new editorial paper, researchers Lilia Gheghiani and Zheng Fu from Virginia Commonwealth University discuss a recent study using their team's new genetically engineered mouse (GEM) model to assess the ability of PLK1 to be a sole driver of oncogenic transformation in vivo. Their editorial was published in Oncotarget's Volume 14 on June 27, 2023, and entitled, “The dark side of PLK1: Implications for cancer and genomic instability.” Full blog - https://www.oncotarget.org/2023/06/29/novel-gem-model-unveils-plk1s-role-in-tumorigenesis/ Paper DOI - https://doi.org/10.18632/oncotarget.28456 Correspondence to - Zheng Fu - zheng.fu@vcuhealth.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28456 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, polo-like kinase 1 (PLK1), oncogene, chromosomal instability, cell cycle checkpoints, tumorigenesis About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

A study demonstrating the health equity impact of Virta Health's diabetes reversal platform highlights the potential of digital health solutions in addressing disparities in healthcare outcomes. Fast Five hosts Sean Whooley and Danielle Kirsh go over the critical points of the study and who the company found is most affected by diabetes. BioSig's expansion of research and development efforts in machine learning and artificial intelligence (AI) for cardiac arrhythmia treatment signifies the growing role of AI in improving patient care. Whooley details what the company plans to use AI for and how optimistic executives are. Medline recently announced that it is promoting from within to fill the CEO and president positions opening up at the privately-held medtech giant. Hear who is taking over the corner office and how this transition could be crucial in shaping the company's future.  Carthera's successful Series B funding round, raising $40M, underscores the growing interest and investment in innovative therapies for neuro-oncology. The Fast Five hosts discuss the technology driving the funding round and its potential applications. Masimo's loss of board seats to activist investor Politan suggests a potential shift in the company's governance and strategic direction. Learn about Masimo's response and what investors think the next step should be for Masimo in today's episode. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.

Host Amy Guth talks with Crain's Dennis Rodkin about news from the local housing market and with local real estate agent Mike Conner, who has a message for Chicago residents: Please don't leave. Plus: Invest South/West projects ring up sky-high construction costs, Medline names new CEO, unemployment nearing record low around metro Chicago and expect to pay less for beef, more for booze this Independence Day.

A new editorial paper was published in Oncotarget's Volume 14 on June 21, 2023, entitled, “Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability.” The successful development of the BCL-2 inhibitor venetoclax, currently approved for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), encouraged the development of inhibitors that target other antiapoptotic proteins, particularly Myeloid Leukemia 1 (MCL-1). MCL-1 is among the top genes amplified in several cancers and is implicated in cancer progression, drug resistance and poor prognosis. It protects cancer cells from apoptosis and decreases their sensitivity to targeted agents or chemotherapeutics. In this new editorial, researchers Shady I. Tantawy, Natalia Timofeeva, Ana Hernandez, Aloke Sarkar and Varsha Gandhi from The University of Texas MD Anderson Cancer Center discussed their recent investigation into the mechanism of MCL-1 inhibitor (MCL-1i)-induced Mcl-1 protein stability. The team explored underlying molecular mechanisms that contribute to MCL-1i-induced MCL-1 protein accumulation and its implications. Their study revealed a complex and multifaceted nature of MCL-1 protein accumulation in B-cell malignancies upon treatment with MCL-1i (AMG-176 and AZD5991). “Collectively, these findings may have important implications for the development of next-generation MCL-1i with improved efficacy and safety profiles.” DOI - https://doi.org/10.18632/oncotarget.28440 Correspondence to - Aloke Sarkar - asarkar@mdanderson.org, and Varsha Gandhi - vgandhi@mdanderson.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28440 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - AMG-176, AZD5991, B-cell leukemia, MCL-1 inhibitor, MCL-1 protein About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

A new research paper was published in Oncotarget's Volume 14 on June 21, 2023, entitled, “Diphenyl ditelluride anticancer activity and DNA topoisomerase I poisoning in human colon cancer HCT116 cells.” Diphenyl ditelluride (DPDT) is an organotellurium (OT) compound with pharmacological properties, including antioxidant, antigenotoxic and antimutagenic activities when applied at low concentrations. However, DPDT as well as other OT compounds also show cytotoxicity against mammalian cells when treatments occur at higher drug concentrations. The underlying mechanisms of toxicity of DPDT against tumor cells have previously been poorly explored. In this new study, researchers André Luiz Mendes Juchem, Cristiano Trindade, Juliana Bondan da Silva, Miriana da Silva Machado, Temenouga Nikolova Guecheva, Jaqueline Cesar Rocha, Jenifer Saffi, Iuri Marques de Oliveira, João Antonio Pêgas Henriques, and Alexandre Escargueil from the Federal University of Rio Grande do Sul, Sorbonne Université, Federal University of Health Sciences of Porto Alegre, Lutheran University of Brazil, Bulgarian Academy of Sciences, and University of Vale do Taquari aimed to investigate the effects of DPDT against both human cancer and non-tumorigenic cells. “Together, our results will help to better define DPDT as a potential drug candidate for treating CRC [colorectal cancer].” The researchers used the colonic HCT116 cancer cells and the MRC5 fibroblasts as models. Their results showed that DPDT preferentially targets HCT116 cancer cells when compared to MRC5 cells with IC50 values of 2.4 and 10.1 μM, respectively. This effect was accompanied by the induction of apoptosis and a pronounced G2/M cell cycle arrest in HCT116 cells. Furthermore, DPDT induces DNA strand breaks at concentrations below 5 μM in HCT116 cells and promotes the occurrence of DNA double strand breaks mostly during S-phase as measured by γ-H2AX/EdU double staining. Finally, DPDT forms covalent complexes with DNA topoisomerase I, as observed by the TARDIS assay, with a more prominent effect observed in HCT116 than in MRC5 cells. Taken together, the results of this study show that DPDT preferentially targets HCT116 colon cancer cells likely through DNA topoisomerase I poisoning. “This makes DPDT an interesting molecule for further development as an anti-proliferative compound in the context of cancer.” Read the full paper: DOI: https://doi.org/10.18632/oncotarget.28465 Correspondence to: João Antonio Pêgas Henriques, Alexandre Escargueil Email: pegas.henriques@ufrgs.br, alexandre.escargueil@gmail.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28465 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - colorectal cancer, HCT116, diphenyl ditelluride, organotellurium, topoisomerase I About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

A new research perspective was published in Oncotarget's Volume 14 on June 19, 2023, entitled, “Targeting GITR in cancer immunotherapy – there is no perfect knowledge.” In this new perspective, researchers Diwakar Davar and Roberta Zappasodi from the University of Pittsburgh Medical Center (UPMC), University of Pittsburgh, Weill Cornell Medical College, and Weill Cornell Graduate School of Medical Sciences discuss the glucocorticoid-induced TNFR-related protein (GITR), belonging to the TNFR superfamily (TNFRSF) and stimulating both the acquired and innate immunity. GITR is broadly expressed on immune cells, particularly regulatory T cells (Tregs) and natural killer (NK) cells. “Given its potential to promote T effector function and impede Treg immune suppression, GITR is an attractive target for cancer immunotherapy.” Preclinically, GITR agonists have demonstrated potent anti-tumor efficacy singly and in combination with a variety of agents, including PD-1 blockade. Multiple GITR agonists have been advanced into the clinic, although the experience with these agents has been disappointing. Recent mechanistic insights into the roles of antibody structure, valency, and Fc functionality in mediating anti-tumor efficacy may explain some of the apparent inconsistency or discordance between preclinical data and observed clinical efficacy. Overall, the clinical results obtained so far with GITR agonist agents have demonstrated specific immune effects in the expected immune cell populations based on preclinical studies. However, these effects have not produced substantial therapeutic activity in human cancer patients. A maturing understanding of the immune responses to GITR agonism in human cancer has clarified novel issues specific to drug development in this space including Ab structure (monospecific and bispecific mAbs and co-stimulatory GITR ligands), Ab valency, and Fc functionality. “This improved understanding of the immune responses to GITR agonism in patients should be kept in consideration for the design of novel rational combinations or treatment regimens in earlier disease settings where immunotherapy is gradually becoming the treatment of choice.” DOI - https://doi.org/10.18632/oncotarget.28461 Correspondence to - Diwakar Davar - davard@upmc.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28461 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, immunotherapy, programmed death-1 (PD-1), cytotoxic T-lymphocyte Antigen-4 (CTLA-4), glucocorticoid-induced TNFR-related protein (GITR) About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

A new research paper was published in Oncotarget's Volume 14 on June 19, 2023, entitled, “Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.” Androgen deprivation therapy (ADT) can lead to metabolic syndrome (MS) and is implicated in ADT-resistance. Metformin showed antineoplastic activity through mTOR inhibition secondary AMPK-activation. To investigate whether metformin mitigated ADT-related MS, researchers Devalingam Mahalingam, Salih Hanni, Anthony V. Serritella, Christos Fountzilas, Joel Michalek, Brian Hernandez, John Sarantopoulos, Paromitta Datta, Ofelia Romero, Sureshkumar Mulampurath Achutan Pillai, John Kuhn, Michael Pollak6, and Ian M. Thompson from the University of Texas Health Science Center, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Roswell Park Cancer Institute, Mays Cancer Center at University of Texas Health, Audie Murphy VA Hospital, McGill University, and Christus Health conducted a randomized double-blind phase II trial of metformin 500 mg TID or placebo in non-diabetic patients with biochemically-relapsed or advanced prostate cancer (PC) due for ADT. “To test these hypotheses, we conducted a phase II randomized, placebo-controlled, prospective study of metformin vs. placebo in patients with advanced, castrate sensitive PC treated with ADT (NCT:01620593).” Fasting serum glucose, insulin, PSA, metformin, weight, and waist circumference (WC) were measured at baseline, week 12 and 28. The primary endpoint was a group of MS metrics. Secondary endpoints include PSA response, safety, serum metformin concentrations and analysis of downstream an mTOR target, phospho-S6-kinase. Thirty-six men were randomized to either metformin or placebo. Mean age was 68.4. Mean weight, WC and insulin levels increased in both arms. At week 12 and 28, no statistical differences in weight, WC or insulin were observed in either arm. No significant difference in percentage of patients with PSA

The Ride for Roswell is one of the nation's largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 27 years to celebrate cancer survivors, pay tribute to lives that have been lost, and to work together to support research and find a cure. When its doors opened in Buffalo in 1898, Roswell Park Comprehensive Cancer Center was the first cancer research-focused institution in the world. Today, this institution is one of only four National Cancer Institute-designated comprehensive cancer centers in the state of New York. Roswell Park Comprehensive Cancer Center is ranked by U.S. News & World Report as one of the best cancer hospitals in the United States. The Ride for Roswell started in 1989 when Mitch Flynn, owner of the advertising agency Flynn & Friends, met Katherine Gioia. Katherine was a four-year-old patient battling a rare form of cancer. After Katherine's death (less than a year after her diagnosis), Katherine's mother, Anne Gioia, and aunt, Donna Gioia, founded the Roswell Park Alliance Foundation in her memory to raise money for cancer research and treatment. On June 29, 1996, Mitch and Alliance Foundation staff launched the first Ride for Roswell. In the 27 years since then, thanks to over 127,000 riders and thousands of volunteers, the Ride for Roswell has raised over $67 million to fund cancer research. The event has become one of the largest charity rides in the United States. Full press release - https://www.oncotarget.net/2023/06/19/oncotarget-sponsors-2023-ride-for-roswell/ Join Team Open Access - https://give.roswellpark.org/site/TR/SpecialEvents/General?team_id=15232&pg=team&fr_id=1830 About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

A new review paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “ACSL4: biomarker, mediator and target in quadruple negative breast cancer.” Breast cancer is a heterogeneous disease for which effective treatment depends on correct categorization of its molecular subtype. For the last several decades this determination has relied on hormone receptor status for estrogen, progesterone and HER2. More recently, gene expression data have been generated that further stratify both receptor-positive and receptor-negative cancers. In this new review, researcher Marie E. Monaco from NYU Grossman School of Medicine and VA NY Harbor Healthcare System discusses the fatty acid-activating enzyme, ACSL4, which has been demonstrated to play a role in the malignant phenotype of a variety of cancers, including breast. This lipid metabolic enzyme is differentially expressed as a function of subtype in breast tumors, with highest expression observed in the mesenchymal (claudin low) and basal-like subtypes. “ACSL4 is one of five mammalian enzyme isoforms responsible for activation (thioesterification) of long-chain fatty acids as a prerequisite to their further utilization in lipid biosynthetic and fatty acid oxidative pathways [1].” Here, Dr. Monaco reviews data that support the potential of utilizing ACSL4 status as both a biomarker of molecular subtype and a predictor of response to a variety of targeted and non-targeted treatment regimens. The ability of ACSL4 to induce a more aggressive phenotype suggests it might be a potential target for inhibition in the treatment of breast cancer. Additional studies are needed to demonstrate the utility of this protein as both a biomarker and target in the classification and treatment of breast cancer. “Based on these findings, we suggest 3 expanded roles for ACSL4: 1. as a biomarker for classification of breast cancer subtypes; 2. as a predictor of sensitivity to hormone-based and certain other therapies; and 3. as a target for the development of new treatment modalities.” DOI - https://doi.org/10.18632/oncotarget.28453 Correspondence to - Marie E. Monaco - mem6@nyu.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28453 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - ACSL4, breast cancer, ferroptosis, molecular subtype, quadruple negative breast cancer About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

A new research paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.” Despite advances in therapies treating non-Hodgkin's lymphoma (NHL), 20~40% of patients experience relapsed or refractory disease. While solid tumors with homologous recombination deficiencies have been successfully targeted with synthetic lethal agents such as poly-ADP ribose polymerase (PARP) inhibitors, such synthetic lethality strategy has not yet been approved to treat patients with NHL. In this new study, researchers Jianli Zhou, Drew Sturtevant, Cassie Love, Aditya Kulkarni, Neha Biyani, Umesh Kathad, Elizabeth Thacker, Sandeep Dave, and Kishor Bhatia from Lantern Pharma Inc., Duke University and Data Driven Bioscience investigated the mechanism of action (MoA) and therapeutic potential of a new-generation acylfulvene compound, LP-284, in both in vitro and in vivo NHL models. “Here, we aimed to characterize LP-284's antitumor efficacy in NHL models and further elucidate its mechanisms of action.” One of LP-284's MoA includes inducing the repair of double-strand DNA break (DSB). The researchers found that LP-284 exerts nanomolar potency in a panel of hematological cancer cell lines including fifteen NHL cell lines. In vivo, LP-284 treatment prolongs the survival of mantle cell lymphoma (MCL) cell line JeKo-1 derived xenograft mice by two-fold and shows increased efficacy over bortezomib and ibrutinib. In addition, LP-284 is capable of inhibiting tumor growth of JeKo-1 xenografts that are refractory to bortezomib or ibrutinib. They further showed that LP-284 is particularly lethal in cells with deficient DNA damage response and repair, a targetable vulnerability in NHL. “In conclusion, our study has demonstrated LP-284 as a novel and potent acylfulvene drug that can suppress tumor growth in NHL models and cells with HR or TC-NER deficiency.” DOI - https://doi.org/10.18632/oncotarget.28454 Correspondence to - Jianli Zhou - jianli@lanternpharma.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28454 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - non-Hodgkin's lymphoma, DNA damage, homologous recombination repair, transcription-coupled nucleotide excision repair, ATM About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

A new research perspective was published in Oncotarget's Volume 14 on May 19, 2023, entitled, “Targeting the Src N-terminal regulatory element in cancer.” The signaling pathways displayed by cancer cells are often composed of the same components as the physiological ones, yet the overall result is a pathological deregulation. In this new paper, researchers Betlem Mezquita, Marjorie Reyes-Farias and Miquel Pons from the Universitat de Barcelona and Universitat Internacional de Catalunya discuss the non-receptor protein tyrosine kinase Src as a good example. “Src, the first discovered oncogene, is the leading member of the Src family of kinases (SFK) that includes Fyn, Yes, Blk, Yrk, Fgr, Hck, Lck, and Lyn.” Src is the first described proto-oncogene and a demonstrated player in cancer progression, as it affects proliferation, invasion, survival, cancer stemness, and drug resistance. Src activation is linked to poor prognosis in many cancer types, yet mutations in this protein are rarely observed. In addition, being a demonstrated cancer target, unspecific inhibition of the kinase activity has proven inefficient in clinics since the inhibition of Src in non-cancerous cells results in unacceptable toxicity. Thus, there is a need for new target regions in Src that could inhibit Src activity only in certain cell types, e.g., cancer cells, while maintaining the normal physiological activity in healthy cells. The Src N-terminal regulatory element (SNRE) includes the poorly studied intrinsically disordered region with unique sequences for each of the members of the Src family. In this perspective, the researchers discuss the non-canonical regulatory mechanisms involving the SNRE and their potential use as oncotargets. “Our group has designed a screening system to search chemical libraries for binders of the Src SNRE [88] and we are currently following up a promising lead.” DOI: https://doi.org/10.18632/oncotarget.28434 Correspondence to: Miquel Pons - mpons@ub.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28444 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords: Src family kinases, intrinsically disordered proteins, SNRE, cell-type selective drugs, drug resistance About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC).” Lung cancer is the number one cause of mortality among all types of cancer worldwide. Its treatment landscape has shifted from the classic chemotherapy alone to newer regimens based on the discovery of new immunotherapy and targeted therapy drugs. However, chemotherapy is still an option for treatment of advanced non-small cell lung cancer (NSCLC) after progression on immunotherapy alone or in combination with first-line chemotherapy. This new retrospective study, by researchers Hazem I. Assi, Maroun Bou Zerdan, Mohammad Hodroj, Makram Khoury, Nour Sabiha Naji, Ghid Amhaz, Reine Abou Zeidane, and Fadi El Karak from the American University of Beirut Medical Center and Hotel Dieu de France University Hospital, was based on chart review of patients diagnosed with advanced NSCLC cases who received Docetaxel as second or third line after being treated by immunotherapy and/or chemotherapy in previous lines. The data was collected from the medical records of physicians' clinics in three different hospital centers in Lebanon over the period of 5 years from July 2015 until December 2020. February 2021 was data analysis cut off time. “The main aim [of this study] was to assess the role of Docetaxel post-chemoimmunotherapy for patients with diagnosed NSCLC.” A total of 21 patients were included in this study. The majority of our patients were males (81%). As for histologic type, most patients had non-squamous lung cancer (67%) as compared to 33% who had squamous lung cancer. Overall, their study reported a 24% response rate to Docetaxel including stable disease and partial response and a median progression free survival (PFS) of 3 months. The mean time interval elapsed from diagnosis to the initiation of Docetaxel was 11.5 months. “New therapeutic options should be validated for the treatment of NSCLC in the second and subsequent lines of therapy considering the poor prognosis of this disease. The chemotherapy in second and third line may keep an important role in the treatment after progression on newer agents, but it needs more evidence in prospective studies including a larger number of patients.” DOI - https://doi.org/10.18632/oncotarget.28444 Correspondence to - Fadi El Karak - Felkarak@yahoo.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28444 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - chemotherapy, immunotherapy, non-small cell lung cancer About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.” The brother of the regulator of imprinted sites (BORIS), 11 zinc-finger transcription factors, is a member of the cancer-testis antigen (CTA) family. It is mapped to chromosome number 20q13.2 and this region is genetically linked to the early onset of breast cancer. In the current study, researchers Mohammad Salman Akhtar, Naseem Akhter, Arshi Talat, Raed A. Alharbi, Abdulmajeed A.A. Sindi, Faisal Klufah, Hanan E. Alyahyawi, Abdulmohsen Alruwetei, Abrar Ahmad, Mazin A. Zamzami, SVS Deo, Syed Akhtar Husain, Osama A. Badi, and Mohammad Jahir Khan from Al-Baha University, Jamia Millia Islamia, ITS Dental College, Qassim University, King Abdulaziz University, All India Institute of Medical Sciences (AIIMS), Henry Ford Health System, and Jawahar Lal Nehru University analyzed the correlation between BORIS mutations and the expression of the protein in breast cancer cases. “The present study is to find out the mutations of BORIS genes in hot spot exons by PCR-SSCP and by automated DNA sequencing in breast cancer tissue samples along with adjacent normal samples.” A population-based study including a total of 155 breast cancer tissue samples and an equal number of normal adjacent tissues from Indian female breast cancer patients was carried out. Mutations of the BORIS gene were detected by polymerase chain reaction-single standard confirmation polymorphisms (PCR-SSCP) and automated DNA sequencing and by immunohistochemistry for BORIS protein expression were performed. The observed findings were correlated with several clinicopathological parameters to find out the clinical relevance of associations. “The BORIS mutations and high protein expression occur frequently in carcinoma of the breast suggesting their association with the onset and progression of breast carcinoma. Further, the BORIS has the potential to be used as a biomarker.” DOI - https://doi.org/10.18632/oncotarget.28442 Correspondence to - Mohammad Salman Akhtar - mdsalmanakhtar@yahoo.com, milyas@bu.edu.sa Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28442 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - BORIS, breast cancer, mutation, transcription factor, PCR-SSCP About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment.” The long non-coding RNA (lncRNA) MALAT1 is a regulator of oncogenesis and cancer progression. MAPK-pathway upregulation is the main event in the development and progression of human cancer, including melanoma and recent studies have shown that MALAT1 has a significant impact on the regulation of gene and protein expression in the MAPK pathway. However, the role of MALAT1 in regulation of gene and protein expression of the MAPK-pathway kinases RAS, RAF, MEK, and ERK in melanoma is largely unknown. In this study, researchers Valentin Feichtenschlager, Yixuan James Zheng, Wilson Ho, Linan Chen, Ciara Callanan, Christopher Chen, Albert Lee, Jose Ortiz, Klemens Rappersberger, and Susana Ortiz-Urda from the University of California San Francisco and Medical University Vienna demonstrated the impacts of antisense oligonucleotide (ASO)-based MALAT1-inhibition on MAPK-pathway gene regulation in melanoma. “Our results showed that MALAT1-ASO treatment decreased BRAF RNA expression and protein levels, and MALAT1 had increased correlation with MAPK-pathway associated genes in melanoma patient samples compared to healthy skin.” Additionally, drug-induced MAPK inhibition upregulated MALAT1-expression, a finding that resonates with a paradigm of MALAT1-expression presented in this work: MALAT1 is downregulated in melanoma and other cancer types in which MALAT1 seems to be associated with MAPK-signaling, while MALAT1-ASO treatment strongly reduced the growth of melanoma cell lines, even in cases of resistance to MEK inhibition. MALAT1-ASO treatment significantly inhibited colony formation in vitro and reduced tumor growth in an NRAS-mutant melanoma xenograft mouse model in vivo, while showing no aberrant toxic side effects. “Our findings demonstrate new insights into MALAT1-mediated MAPK-pathway gene regulation and a paradigm of MALAT1 expression in MAPK-signaling-dependent cancer types. MALAT1 maintains essential oncogenic functions, despite being downregulated.” DOI - https://doi.org/10.18632/oncotarget.28447 Correspondence to - Valentin Feichtenschlager - valentin.feichtenschlager@ucsf.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28447 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - MALAT1, MAPK-pathway, BRAF, melanoma, antisense oligonucleotides About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Blog summary: “Role of creatine shuttle in colorectal cancer cells.” _____________________________________________ Since the 1992 Barcelona Olympics, creatine supplementation has increased in popularity and grown to widespread use among the mainstream public. Creatine is a naturally occurring compound, primarily stored in skeletal muscle and involved in energy production for high-intensity activities—enhancing performance and supporting muscle growth and strength. The process by which creatine is transported into the muscles and utilized for energy production is referred to as the creatine shuttle. While it is a useful mechanism for healthy muscles, the creatine shuttle has also been implicated in cancer. “The creatine shuttle is highlighted in cancer as a source of energy for cancer cells that display aggressive proliferation, and aberrant creatine kinase (CK) levels are known to be associated with many malignancies and mitotic control [7].” In a new study, researchers Mayu Kita, Rina Fujiwara-Tani, Shingo Kishi, Shiori Mori, Hitoshi Ohmori, Chie Nakashima, Kei Goto, Takamitsu Sasaki, Kiyomu Fujii, Isao Kawahara, Ujjal Kumar Bhawal, Yi Luo, and Hiroki Kuniyasu from Nara Medical University, Saveetha University and Nantong University hypothesized that the creatine shuttle is involved in energy metabolism and other adenosine triphosphate (ATP) supply in cancer cells. On May 19, 2023, their new research paper was published in Oncotarget's Volume 14, entitled, “Role of creatine shuttle in colorectal cancer cells.” Full blog - https://www.oncotarget.org/2023/05/25/can-the-creatine-shuttle-be-targeted-to-fight-colorectal-cancer/ DOI - https://doi.org/10.18632/oncotarget.28436 Correspondence to - Hiroki Kuniyasu - cooninh@zb4.so-net.ne.jp, and Rina Fujiwara-Tani - rina_fuji@naramed-u.ac.jp Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28436 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - creatine kinase B, mitochondrial creatine kinase, ATP metabolism, phosphorylation signal, stemness About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Dr. Gopal C. Kundu from KIIT Deemed to be University in Odisha, India, describes a recent editorial he co-authored that was published by Oncotarget in Volume 14, entitled, “The molecular dialogue between the tumor cells and fibroblasts.” DOI - https://doi.org/10.18632/oncotarget.28405 Correspondence to - Gopal C. Kundu - gopalc.kundu@kiit.ac.in Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28405 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - CAFs, heterogeneity, myofibroblasts, drug resistance, osteopontin About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Paul Schwitzer, current Vice President of American Biotech Labs, graduated from the University of Utah with a Bachelors of Science in Organizational Communications. He went on to work for 8 years as an antimicrobial specialist at Abbott Laboritories, followed by a managerial position in Medline's advance wound care division for another eight years. Paul is a lifelong Utah resident, has been married to his wife Kari for 24 years, and has four children tha mean everything to him. In today's episode, Paul and I discuss all things colloidal silver. He teaches what it is, its amazing health benefits, and what to look for when purchasing colloidal silver. For 15% off your order at Clearly Filtered, Use the code JUSTINGREDIENTS at https://www.clearlyfiltered.com/?rfsn=4850831.504d9f5